UB Paderborn / Katalog / Suche / in CDI

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Journal of clinical oncology, 2009-03, Vol.27 (8), p.1227-1234

2009

Volltextzugriff (PDF)

Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases

JTO clinical and research reports, 2023-04, Vol.4 (4), p.100483-100483, Article 100483

2023

Volltextzugriff (PDF)

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC

JTO clinical and research reports, 2022-07, Vol.3 (7), p.100341-100341, Article 100341

2022

Volltextzugriff (PDF)

Tumor volume measurement error using computed tomography imaging in a phase II clinical trial in lung cancer

Journal of medical imaging (Bellingham, Wash.), 2016-07, Vol.3 (3), p.035505-035505

2016

Volltextzugriff (PDF)

Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence

Clinical pharmacology and therapeutics, 2021-11, Vol.110 (5), p.1162-1163

2021

Volltextzugriff (PDF)

A master screening study to determine biomarker status and trial eligibility for patients with malignant tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS8608-TPS8608

2023

Volltextzugriff (PDF)

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

The Lancet (British edition), 2005-10, Vol.366 (9496), p.1527-1537

2005

Volltextzugriff (PDF)

Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial

Nature medicine, 2024-07, Vol.30 (7), p.1923-1932

2024

Volltextzugriff (PDF)

Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK -positive ( ALK +) solid tumors in a histology-agnostic setting

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS3155-TPS3155

2021

Volltextzugriff (PDF)

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015)

Journal of thoracic oncology, 2014-06, Vol.9 (6), p.848-855

2014

Volltextzugriff (PDF)

Efficacy/safety of entrectinib in patients (pts) with ROS1 -positive (ROS1 +) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST)

Journal of clinical oncology, 2022-06, Vol.40 (17_suppl), p.LBA9023-LBA9023

2022

Volltextzugriff (PDF)

Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK + NSCLC

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9518-9518

2020

Volltextzugriff (PDF)

Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT200-CT200

2019

Volltextzugriff (PDF)

Clinical genotyping and efficacy outcomes: Exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2014-10, Vol.86 (1), p.67-72

2014

Volltextzugriff (PDF)

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Update From the Phase III ALESIA Study

JTO clinical and research reports, 2024-06, p.100700, Article 100700

2024

Volltextzugriff (PDF)

A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens

Cancer chemotherapy and pharmacology, 2003-08, Vol.52 (2), p.113-118

2003

Volltextzugriff (PDF)

In Reply

Journal of clinical oncology, 2004-06, Vol.22 (12), p.2513-2514

2004

Volltextzugriff (PDF)

C1-06: BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S360-S361

2007

Volltextzugriff (PDF)

Pathologic complete response and survival advantage in esophageal cancer: old news

Journal of clinical oncology, 2004-06, Vol.22 (12), p.2513; author reply 2513-2513

Kraut, Michael J

2004

Volltextzugriff (PDF)

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer : results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Commentary

The Lancet (British edition), 2005, Vol.366 (9496), p.1507-1508

2005

Volltextzugriff (PDF)

Cognitive and physical rehabilitation of intensive care unit survivors: Results of the RETURN randomized controlled pilot investigation

Critical care medicine, 2012-04, Vol.40 (4), p.1088-1097

2012

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Tumor volume measurement error using computed tomography imaging in a phase II clinical trial in lung cancer

Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence

A master screening study to determine biomarker status and trial eligibility for patients with malignant tumors

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial

Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK -positive ( ALK +) solid tumors in a histology-agnostic setting

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015)

Efficacy/safety of entrectinib in patients (pts) with ROS1 -positive (ROS1 +) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST)

Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK + NSCLC

Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC

Clinical genotyping and efficacy outcomes: Exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Update From the Phase III ALESIA Study

A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens

In Reply

C1-06: BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)

Pathologic complete response and survival advantage in esophageal cancer: old news

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer : results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Commentary

Cognitive and physical rehabilitation of intensive care unit survivors: Results of the RETURN randomized controlled pilot investigation

Suchergebnisse filtern